Clinical trials: Infection, COVID-19
SARS (Severe Acute Respiratory Syndrome), Cytokine Storm
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure.
- Conditions
- SARS (Severe Acute Respiratory Syndrome), Cytokine Storm, ARDS, Human, COVID-19
- Trial name
- COVID-19-HBO (NCT04327505)
- Testing
- Hyperbaric oxygen
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 34 people
- Sponsor
- Karolinska Institutet
COVID-19
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days.
- Trial name
- NCT04313023
- Testing
- PUL-042 Inhalation Solution
- Where
- 15 sites in United States
- Volunteers
- 217 people
- Sponsor
- Pulmotect, Inc.
COVID-19
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of Boost-2867, given intramuscular (IM) with or without adjuvant or intranasal (IN) without adjuvant, as a booster dose to previously…
- Trial name
- NCT07221162
- Testing
- Aluminum Hydroxide Suspension, Boost-2867, CpG 7909
- Where
- 8 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Glucocorticoids Toxicity, COVID-19
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
The goal of this interventional study is to evaluate the pharmacokinetics, safety, and tolerability of 101-PGC-005 in healthy, adult, human subjects.
- Conditions
- Glucocorticoids Toxicity, COVID-19, Infectious Disease, Virus Diseases
- Trial name
- NCT05619770
- Testing
- 101-PGC-005
- Where
- India
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- 101 Therapeutics
Artificial Intelligence, Deep Learning
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical…
- Conditions
- Artificial Intelligence, Deep Learning, Pathology, Molecular, Medical Informatics
- Trial name
- NCT05046366
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
COVID-19
Immune Response of Asymptomatic EHPAD Employees Infected With COVID-19
The investigators performed in April 2020, a screening campaign of asymptomatic staff working in elderly nursing homes in Paris France (EHPAD), where the virus had been circulating actively in March and April 2020.
- Trial name
- SERASYMPTO (NCT05128656)
- Testing
- serology
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing…
- Trial name
- C4591068 (NCT06703190)
- Testing
- Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
COVID-19
Message Encouraging Vaccination in Preparation for the Holidays
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned.
- Trial name
- NCT05612360
- Testing
- COVID Booster text messages
- Where
- United States
- Volunteers
- 520,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Covid19
Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
This is a phase III, randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a candidate adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05005559
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 16,876 people, healthy volunteers welcome
- Sponsor
- Cinnagen
ARDS, Human, Coronavirus
Sevoflurane in COVID-19 ARDS (SevCov)
The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering…
- Trial name
- NCT04355962
- Testing
- Sevoflurane, Intravenous drug
- Where
- 4 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- University of Zurich
Ebola Virus Disease, COVID-19
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases.
- Trial name
- NCT06587503
- Testing
- BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
COVID-19
Intradermal COVID-19 Vaccination in the Immunocompromised
COVID-19 is an infectious disease caused by SARS-CoV-2 virus, causing millions of deaths around the globe since the beginning of the pandemic.
- Trial name
- NCT05736913
- Testing
- ID BNT162b2 vaccine, IM BNT162b2 vaccine
- Where
- Hong Kong
- Volunteers
- 130 people
- Sponsor
- The University of Hong Kong
Pregnancy, Covid-19
Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children
This study aim is to assess impact of COVID-19 infection during pregnancy on outcome of pregnancy, and on developement of the child in early life.
- Trial name
- ELIKYA COVID (NCT04432779)
- Testing
- no intervention
- Where
- Belgium
- Volunteers
- 1,362 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Mental Health Issue, Depressive Symptoms
Piloting +Connection is Medicine / The Healing Spirits Program
This study aims to assess what benefit, if any, an individualized coping plan and facilitating connections to care through referral coordination in conjunction with culturally tailored caring messages, (herein called the…
- Conditions
- Mental Health Issue, Depressive Symptoms, Anxiety
- Trial name
- NCT05424679
- Testing
- Safety Planning Intervention, Caring Contacts
- Where
- 4 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
COVID-19, Coronavirus Disease 2019
SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study
SARS-CoV-2 Nucleic Acid Detection Kit is an In Vitro Diagnostic (IVD) medical device intended for RNA detection of SARS-CoV-2 in human specimens using multiplex real-time polymerase chain reaction (RT-PCR) technology.
- Conditions
- COVID-19, Coronavirus Disease 2019, COVID-19 Pandemic, Diagnoses Disease
- Trial name
- CPS CW008 (NCT05492227)
- Testing
- Left-overs
- Where
- Spain
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- TransGen Biotech Co., LTD
COVID-19 SARS-CoV-2 Infection
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
The objective of this study is to evaluate the effectiveness of SCTV01E in healthy people
- Trial name
- NCT05683561
- Testing
- CoronaVac, SCTV01E
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Pulmonary Fibrosis, Interstitial Lung Disease
The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19
Up to a third of patients who recovered from SARS coronavirus (SARS-CoV) had a 20% decline in lung function with a long term reduction in exercise capacity and SF-36 health status a year after infection.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Covid19
- Trial name
- MONACO (NCT04805086)
- Testing
- MON002
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Coronavirus Infection
An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso
This is an observational study to evaluate the effectiveness of the combinations Hydroxychloroquine + Azithromycin (HCQ-AZ) and Chloroquine + Azithromycin (CQ-AZ) in the treatment of Coronavirus (Covid-19) infection in Burkina…
- Trial name
- CHLORAZ (NCT04445441)
- Where
- 2 sites in Burkina Faso
- Volunteers
- 153 people
- Sponsor
- Centre Muraz
Hypertension, Hypoxia
The VISION-Acute Study
AIM: We propose an innovative approach using Lifelight® smart technology that will enable the continued provision of high level patient care at the same time as reducing pressure on nursing and equipment resources.
- Conditions
- Hypertension, Hypoxia, Hypotension
- Trial name
- NCT04589923
- Testing
- Lifelight® Data Collect Blood Pressure Group, Lifelight® Data Collect Oxygen Saturation Group
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Xim Limited
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (3~17 years old) Research purpose:Main purpose:To evaluate the safety and tolerability of recombinant New Coronavirus vaccine (CHO cells) in…
- Trial name
- NCT04961359
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.